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Neuroinﬂammation and microglial activation are signiﬁcant processes in Alzheimer’s disease pathology. Recent genome-wide
association studies have highlighted multiple immune-related genes in association with Alzheimer’s disease, and experimental
data have demonstrated microglial proliferation as a signiﬁcant component of the neuropathology. In this study, we tested the
efﬁcacy of the selective CSF1R inhibitor JNJ-40346527 (JNJ-527) in the P301S mouse tauopathy model. We ﬁrst demonstrated the
anti-proliferative effects of JNJ-527 on microglia in the ME7 prion model, and its impact on the inﬂammatory proﬁle, and
provided potential CNS biomarkers for clinical investigation with the compound, including pharmacokinetic/pharmacodynamics
and efﬁcacy assessment by TSPO autoradiography and CSF proteomics. Then, we showed for the ﬁrst time that blockade of
microglial proliferation and modiﬁcation of microglial phenotype leads to an attenuation of tau-induced neurodegeneration and
results in functional improvement in P301S mice. Overall, this work strongly supports the potential for inhibition of CSF1R as a
target for the treatment of Alzheimer’s disease and other tau-mediated neurodegenerative diseases.
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Introduction
Alzheimer’s disease is the most common form of dementia
affecting roughly 6–7% of the population aged 65, and up
to 30% of people aged 85 and over (Hebert et al., 2003;
Qiu et al., 2009). From a pathological perspective,
Alzheimer’s disease is characterized by extensive accumula-
tion of extracellular amyloid-b soluble peptides and pla-
ques, and intracellular neuroﬁbrillary tau tangles, together
with gliosis, neuronal dystrophy and loss, and vascular al-
teration (Sala Frigerio and De Strooper, 2016). The pres-
ence of amyloid plaques and neuroﬁbrillary tangles is
accompanied by a robust innate immune response charac-
terized by microglial activation (Akiyama et al., 2000;
Edison et al., 2008) and expression of pro-inﬂammatory
cytokines and chemokines (Dickson et al., 1993;
Ferna´ndez-Botra´n et al., 2011).
The critical contribution of inﬂammation to Alzheimer’s
disease pathogenesis has been further implicated by recent
genome-wide association studies (GWAS), which highlight
multiple immune-related genes in association with
Alzheimer’s disease (Efthymiou and Goate, 2017), including
the colony-stimulating factor 1 receptor (CSF1R) (Sassi
et al., 2018). This evidence indicates that neuroinﬂammation
and microglial activation are key drivers of Alzheimer’s dis-
ease pathology. Interestingly, CSF1R signalling mediates
microglial proliferation and survival, and both upregulation
of CSF1R and increased proliferation of microglia have been
reported in post-mortem samples from patients with
Alzheimer’s disease (Akiyama et al., 1994; Gomez-Nicola
et al., 2013; Olmos-Alonso et al., 2016).
The importance of neuroinﬂammation in Alzheimer’s dis-
ease is also strongly supported by experimental data from
several rodent models (Heneka et al., 2015). We showed
previously that inhibition of microglial proliferation by
pharmacologically blocking CSF1R ameliorates disease pro-
gression in the APP/PS1 (Olmos-Alonso et al., 2016) model
of Alzheimer’s disease, but also multiple experimental
models of neurodegenerative disease, including prion dis-
ease (Gomez-Nicola et al., 2013) and amyotrophic lateral
sclerosis (ALS) (Martinez-Muriana et al., 2016). Similar re-
sults have been shown using microglial depletion strategies
in 3xTg-ADD (Dagher et al., 2015) and 5xTg-AD models
(Spangenberg et al., 2016; Sosna et al., 2018). Partial de-
pletion of microglia has been also recently tested in aged
Tg2510 mice, but failed to modify tau pathology (Bennett
et al., 2018).
Recent single-cell transcriptomic analysis from
Alzheimer’s disease mice brains has shed some light on
the transcriptional signature of plaque-associated microglia
(named ‘disease-associated microglia’, DAM), in which
there is a two-step switch from a homeostatic (Tmem119,
P2ry12, Cx3cr1 signature) to a pathology-associated
phenotype (Apoe, Trem2, Csf1, Itgax signature), with
TREM2 as a major phenotypic modulator (Keren-Shaul
et al., 2017). This microglial transcriptomic proﬁle has
been also observed in pure tauopathy models including
P301S and P301L mice (Friedman et al., 2018). However,
whether microglial proliferation and associated phenotypic
changes inﬂuence tau pathology, the other major proteino-
pathy of Alzheimer’s disease, and other tauopathies or
tau-mediated neurodegeneration, is not clear.
In this study, we describe the effects of the selective clin-
ically available CSF1R inhibitor JNJ-40346527 (JNJ-527)
on microglia in chronic neurodegeneration. JNJ-527 is a
potent inhibitor of CSF1R tyrosine kinase activity with
high selectivity over similar related kinases, such as KIT
and FLT3 (CSF1R IC50 = 3.2 nM; KIT IC50 = 20 nM;
FLT3 IC50 = 190 nM) (Genovese et al., 2015; Von
Tresckow et al., 2015). Overall, we: (i) demonstrate the
anti-proliferative effects of JNJ-527 upon microglia in the
ME7 prion model and provided potential CNS biomarkers
for the clinical investigation of the compound, including
efﬁcacy assessment by TSPO autoradiography and CSF
proteomics; and (ii) show for the ﬁrst time that blockade
of microglial proliferation and modiﬁcation of microglial
phenotype may lead to the amelioration of tau pathology
and attenuation of neurodegeneration. This work strongly
supports the potential of inhibition of CSF1R as a target
for the treatment of Alzheimer’s disease and other tau-
mediated neurodegenerative diseases.
Materials and methods
In vitro assessment of CSF1R
phosphorylation
The N13 murine microglia cell line (Righi et al., 1991) was
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Thermo Fisher Scientiﬁc), supplemented with 10% foetal
bovine serum and 50 U/ml penicillin/streptomycin (Thermo
Fisher Scientiﬁc). Cells were maintained in T75 ﬂasks at
37C in a 5% CO2 humidiﬁed atmosphere. Cells were plated
at a density of 2  105 cells/cm2 in 6-well plates and cultured
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overnight to allow adherence. Cells were kept in serum-free
medium for 4 h prior to stimulation and then incubated with-
out or with 0.1, 1, 10, 100 or 1000nM of JNJ-527 for 30min.
Recombinant CSF1 (100 ng/ml, R&D Systems) was added to
respective wells for 5min, after which cells were immediately
lysed in RIPA buffer (Thermo Fisher Scientiﬁc), supplemented
with protease and phosphatase inhibitor cocktails (Roche,
Thermo Fisher Scientiﬁc). Protein lysates were concentrated
using Microcon-10 kDa Centrifugal Filter Units (Merck
Millipore), according to manufacturer’s instructions and pro-
tein concentration was determined using the Pierce BCA
Protein Assay Kit (Thermo Fisher Scientiﬁc). For estimation
of IC50, values for CSF1R and ERK1/2 phosphorylation
were modelled in a non-linear regression curve using
GraphPad prism.
Experimental model of prion disease
C57BL/6 J (Harlan) mice were bred and maintained in local
facilities. Mice were housed in groups of 4–10, under a 12-h
light/12-h dark cycle at 21C, with food and water ad libitum.
To induce prion disease, 8–10-week-old mice were anaesthe-
tized with a ketamine/xylazine mixture (85 and 13mg/kg), and
1 ml of either ME7-derived (ME7 animals) brain homogenate
(10% w/v) or normal brain homogenate (NBH animals) was
injected stereotaxically and bilaterally at the coordinates from
bregma: anteroposterior, 2.0mm; lateral, 1.7mm; depth,
1.6mm (Gomez-Nicola et al., 2013). All animals were at
12 weeks post-induction at the beginning of the treatment
period. When required, mice received intraperitoneal BrdU
(7.5mg/ml, 0.1ml/10 g weight in sterile saline; Sigma-Aldrich)
for the 2 days before the end of the experiment. All animal
studies were ethically reviewed and carried out in accordance
with Animals (Scientiﬁc Procedures) Act 1986 and the GSK
Policy on the Care, Welfare and Treatment of Animals.
Experimental model of tauopathy
P301S transgenic mice were developed by Prof. Michel
Goedert, Division of Neurobiology, University of Cambridge
(Cambridge, UK). The detailed description of the animal
model can be found in Allen et al. (2002). Homozygous
P301S and non-transgenic C57BL/6 wild-type mice were
used in this study. Mice were killed at 6, 12, 16 and 20
weeks of age.
Pharmacological treatments
For short-term treatments, JNJ-527 was dissolved in 0.9%
Methocel
TM
and administered daily (morning) for ﬁve consecu-
tive days by oral gavage at doses of 3, 10, 30 and 100mg/kg.
For long term treatments (4–8 weeks), JNJ-527 was incorpo-
rated into mouse chow as previously described by Olmos-
Alonso et al. (2016), for a ﬁnal dose of 30mg/kg with an
average daily ingestion of 5 g of food per mouse. Diet com-
position was identical in terms of fat, protein, etc. content,
with the only addition of the compound. Mouse weight and
food consumption were monitored in all experiments, and no
differences were found between treated and untreated groups.
All the experimental groups were randomized to avoid gender
and cage effects, and all the experiments were performed by
blinded researchers.
Behavioural tests
Multiple tests were performed to detect the onset and progres-
sion of behavioral abnormalities in ME7 (Boche et al., 2006;
Gomez-Nicola et al., 2013) and P301S mice (Scattoni et al.,
2010): open-ﬁeld locomotor activity, and motor performance
on inverted screen, horizontal bar and rotarod test.
Locomotor activity
The open-ﬁeld test was performed using activity monitor soft-
ware (Med Associated). Mice were placed in individual cages
of 27  27 cm for a period of 5min and the total distance
travelled was analysed. The average speed was used as an in-
ternal control of the mouse motor abilities.
Horizontal bar
The test was performed on a 38-cm long metal bar with a
diameter of 0.2 cm that was supported by wooden struts to
a height of 49 cm over a padded bench surface. Mice were held
by the tail and allowed to grip the centre of the bar with their
front paws only. The tail was rapidly released and time taken
to fall off (60 s) or to reach one of the wooden supports (con-
tact with forepaw) was recorded.
Inverted screen
The inverted screen is a 43-cm square of wire mesh consisting
of 12-mm squares of 1-mm diameter wire. It is surrounded by
a 4-cm deep wooden beading, which prevents mice from
climbing on to the other side (Guenther et al., 2001). Mice
were placed in the centre of the grid and the latency to fall was
recorded. One hundred and twenty seconds was considered an
arbitrary maximum.
Rotarod test
Motor coordination, balance and strength of the animals were
assessed using the rotarod test (Brooks and Dunnett, 2009;
Mancuso et al., 2012). All mice were trained three times a
week on the rod rotating with an acceleration of 4–40 rpm
in 5min, for a maximum of 300 s to reach the baseline level
of performance (Scattoni et al., 2010). Animals were then
tested every 2 weeks at the same speed, and the latency to
fall from the rotating rod was measured. Three hundred se-
conds was considered an arbitrary maximum time of remain-
ing on the rotating rod.
Histology
Mice were terminally anaesthetized with an overdose of
sodium pentobarbital and transcardially perfused with 0.9%
saline. Samples were cut in transverse serial sections (35-mm
thick) with a vibrating microtome (brain samples) or cryostat
(spinal cord samples, Leica). For each segment, series of six or
10 sections were sequentially collected free-ﬂoating and kept in
Olmos solution at 20C for brain and spinal cord,
respectively.
To analyse motor neurons preservation, spinal cord sections
were rehydrated for 1min and stained for 2 h with an acidiﬁed
solution of 3.1mM Cresyl violet. Sections were then washed in
distilled H2O for 1min, dehydrated and mounted with DPX
(Mancuso et al., 2011, 2012). Motor neurons were identiﬁed
by their localization in the ventral horn of the stained spinal
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cord sections and quantiﬁed following size and morphological
criteria: only motor neurons with diameters larger than 20 mm
and with polygonal shape and prominent nucleoli were quan-
tiﬁed. Motor neurons present in the lateral site of both ventral
horns were quantiﬁed in four serial sections of L4–L5 seg-
ments (Mancuso et al., 2012, 2016; Martinez-Muriana et al.,
2016).
Immunohistochemistry was performed as described previously
(Mancuso et al., 2016; Martinez-Muriana et al., 2016; Clayton
et al., 2017). Brieﬂy, sections were treated with 10% methanol
and 0.3% H2O2 to block for endogenous peroxidase activity
(only for bright ﬁeld immunohistochemistry), and with 5%
normal serum + 0.5% BSA in phosphate-buffered saline (PBS)
for non-speciﬁc binding. After rinses with PBS-0.1% Tween 20
(PBST), sections were incubated overnight at 4C with rabbit
anti-Iba1 (Wako, 019–19741), anti-PU.1 (Cell Signaling
Technology #2266), anti-AT8 (Thermo Fisher, MN1020),
anti-AT100 (Thermo Fisher, MN1060), anti-phospho-JNK
(Cell Signaling Technology, #9251), anti-phospho-p38 (Cell
Signaling Technology, #4511), anti-BrdU (Biorad, MCA2060).
After washes with PBST, sections were incubated with the
appropriated biotinylated (Vector Labs) or Alexa 488- and
594-conjugated secondary antibodies (Invitrogen). For bright
ﬁeld immunohistochemistry, following rinses sections were
incubated with Vectastain ABC complex (Vectors Labs) and
visualized with diaminobenzidine (DAB) precipitation. Sections
for bright ﬁeld were mounted with DePeX and imaged either
with a Leica DM5000B microscope coupled to a Leica
DFC300FX camera, or by using an Olympus VS110 high
throughput virtual microscopy system (Leica). For immuno-
ﬂuorescence labelling, sections were counterstained with DAPI
and mounted with Mowiol/DABCO (Sigma-Aldrich) mixture.
Sections were visualized on a Leica TCS-SP8 confocal system,
coupled to a Leica CTR6500 camera.
TSPO autoradiography
Mice were terminally anaesthetized with an overdose of
sodium pentobarbital and transcardially perfused with 0.9%
saline. Brains were harvested, frozen in isopentane at a tem-
perature of 40C and stored at 80C. NBH (n = 7), ME7
(n = 8) and ME7 + JNJ-527 (n = 8) mouse brains were coron-
ally cryosectioned at 20 mm and directly mounted onto glass
slides. Slides were incubated at room temperature for 30min in
100mM Tris-HCl containing 1 nM [3H]PK11195 (speciﬁc ac-
tivity 82.7Ci per mmol; Perkin Elmer), washed twice for 6min
in 100mM Tris-HCl, rinsed dipping into dH2O and air dried.
Non-speciﬁc binding was carried out in the presence of 20 mM
PK11195 (Sigma-Aldrich) and 1nM 3H-PK11195. The slides
were exposed to tritium-sensitive ﬁlm (Amersham Hyperﬁlm
MP, GE Healthcare) in autoradiography cassettes together
with a set of tritium standards ([3H]Microscale, American
Radiolabeled Chemicals) for 6 weeks. Sections for speciﬁc
and non-speciﬁc binding were processed together in a paired
protocol. Films were developed using ECOMAX X-ray ﬁlm
processor (PROTEC). Quantitative analysis was performed
using a MCID image analyser (Image Research), and brain
structures were identiﬁed using the mouse brain atlas of
Franklin and Paxinos (1997). All regions of interest (hippo-
campus, cortex and thalamus) were analysed by freehand
drawing tools in three consecutive sections per brain.
Protein analysis
Mice were terminally anaesthetized with an overdose of
sodium pentobarbital and transcardially perfused with 0.9%
saline. Spinal cord samples were homogenized in RIPA buffer
(Thermo Fisher) with protease inhibitors (EASYpack, Roche)
and phosphatase inhibitors (PhosSTOP, Roche). Homogenates
were centrifuged at 1000g and the supernatant was collected.
Protein was quantiﬁed using BCA assay (Thermo Fisher) fol-
lowing the manufacturer’s instructions.
Mesoscale multiplex plate-based assay
Assessment of inﬂammatory cytokines was performed using
the V-PLEX Plus Proinﬂammatory Panel 1 Kit (MesoScale
Discovery), following the manufacturer’s instructions.
Western blot
Twenty micrograms of protein of each sample were run on
SDS-polyacrylamide gels (TGX gels, Bio-Rad), and transferred
to nitrocellulose membranes by using the Trans-Blot Turbo
TM
Transfer System (Bio-Rad). The membranes were blocked with
5% BSA in Tris-buffered saline (TBS) plus 0.1% Tween-20 for
1 h, and then incubated with primary antibodies at 4C over-
night. The primary antibodies used were: anti-AT8 (Thermo
Fisher, MN1020), anti-AT100 (Thermo Fisher, MN1060),
anti-AT180 (Thermo Fisher, MN1040) and total Tau (C-ter-
minal, Dako A0024). After washes with PBST, sections were
incubated with Alexa 488- and 594-conjugated secondary anti-
bodies (Invitrogen). The membranes were imaged using the
ChemiDoc
TM
system (Bio-Rad), and quantiﬁed with FIJI
software.
Analysis of globular tau oligomers and
neurofibrillary tangles
For the analysis of globular tau oligomers, protein extraction
was performed as described previously (Cowan et al., 2015).
Brieﬂy, P301S mice spinal cord (T12–L2) were homogenized in
100 ml buffer (50mM Tris-Cl pH 7.4, 150mM NaCl, 1%
Triton Buffer). Samples were then centrifuged for 2min at
1000g. The supernatant was centrifuged at 186 000g for 2 h
at 4C. The resulting supernatant (S1) represents the aqueous
soluble fraction. The pellet was subsequently resuspended in
5% SDS/TBS buffer (50mM Tris-HCl pH 7.4, 175mM NaCl,
5% SDS) at room temperature and centrifuged at 186 000g for
2 h at 25C. The resulting supernatant (S2) represents the
water insoluble/SDS soluble fraction. The pellet from S2 was
then washed by resuspension again in 5% SDS/TBS buffer
(50mM Tris-HCl pH 7.4, 175mM NaCl, 5% SDS) and cen-
trifuged at 186 000 g for 2 h at 25C. To obtain S3, the ﬁnal
pellet was resuspended in 8M urea, 8% SDS buffer (50mM
Tris-HCl, pH 7.4, 175mM NaCl, 8% SDS, 8M urea) and
shaken for 12–18 h at room temperature. All samples were
diluted in 2 Laemmli buffer and boiled for 5min, and run
on SDS-polyacrylamide gels (TGX
TM
gels, Bio-Rad) as
described above. Membranes were stained using tau antibody
(C-terminal, Dako A0024), and the proportion of globular tau
oligomers was then calculated as the fraction of S3 in the total
amount of tau (S1 + S2 + S3). For assessing for the presence of
neuroﬁbrillary tangles, P301S mice spinal cords were homoge-
nized in 100ml buffer (50mM Tris-Cl pH 7.4, 150mM NaCl,
1% Triton buffer). Samples were centrifuged for 2min at
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1000g. The supernatant was then centrifuged at 100 000g for
30min at 25C. The resulting supernatant (NS1) includes
aqueous and detergent soluble tau, together with globular
tau oligomers. The pellet from NS1 was subsequently
washed by resuspended in 5% SDS/TBS buffer (50mM Tris-
HCl pH 7.4, 175mM NaCl, 5% SDS) and centrifuged at
100 000g for 30min at 25C. The resulting supernatant
(NS2) represents the insoluble neuroﬁbrillary tangles enriched
fraction. All samples were diluted in 2 Laemmli buffer and
boiled for 5min, and run on an SDS-polyacrylamide gel
(TGX
TM
gels, Bio-Rad) as described above. Membranes were
stained using tau antibody (C-terminal, Dako A0024), and the
proportion of neuroﬁbrillary tangles was calculated as the frac-
tion of NS2 in the totality of tau (NS1 + NS2).
Meso scale discovery immunoassay for tau
aggregation
A piece of the spinal cord was homogenized in 150 ml buffer
H (10mM Tris/HCl, 0.8M NaCl, 10% sucrose, 1mM EGTA,
pH 7.6, including complete protease inhibitor (Roche) and
PhosStop phosphatase inhibitor (Roche). Samples were centri-
fuged for 30min at 4C at 20 000g to clear debris.
Supernatant was collected as total homogenate. Using the
BCA method, protein concentration was determined, which
was used to normalize total tau and aggregated measure-
ments. Total tau and aggregated tau content was measured
by a sandwich ELISA set up in a mesoscale discovery plat-
form. During an overnight incubation at 4C, 96-well plates
(Multi-Array plates, Meso Scale Discovery) were coated with
either 1 or 2 mg/ml of antibody, depending on the optimal
conditions of the assay. After a wash step with 0.05%
Tween-20 in PBS, the plates were blocked with 0.1% casein
in PBS for 2 h at room temperature with agitation at 400 rpm.
After another wash step, samples were diluted 1/30 and 1/100
for the aggregation assays and 1/100 and 1/300 for the total
tau assays in blocking buffer and incubated overnight at 4C.
Following the incubation, plates were washed again and incu-
bated with the sulpho-labelled detection antibody, diluted in
blocking buffer, for 2 h at room temperature. Dilution of the
detection antibody is dependent on the assay. Before reading
the plates with the MSD SECTOR Imager 600 (Meso Scale
Discovery), plates were washed again and 150 ml of 2 MSD
Read Buffer T was added. Concentration of tau (ng/ml) mea-
sured by the total tau assays was calculated by a standard
curve of recombinant tau. The amount of aggregated tau
was represented as arbitrary units and calculated by a linear
dilution of a total homogenate preparation of a transgenic
mouse with proven high amount of aggregated tau.
Statistical analysis was conducted in GraphPad, using an un-
paired t-test.
Aptamer capture arrays
Protein was extracted from mouse CSF for 59 mice comprising
NBH n = 29 and ME7 n = 30, with each type receiving JNJ-
527 doses: vehicle control n = 10; 10mg/kg n = 10; 30mg/kg
n = 9, 10. Five microlitres of CSF were hybridized to the
SomaScan Version 3.2 array containing 3999 aptamers
(SomaLogic) as described in the proprietary methods. For the
statistical analysis, 1363 aptamer probes were formally vali-
dated by SomaLogic for cross reaction with mouse proteins
(including the ligand of CSR1R IL-34, but not CSF1). After
quality control, 1202 proteins were used for statistical ana-
lysis. Linear models were used to compare the experimental
variables and discern effect of inhibitor dosage and mouse
model of protein expression, whereby expression was deﬁned
as the outcome measure with model (ME7/NHB) and drug
dosage (0, 10, 30) as dependent variables. Proteins with dif-
ferential expression changes mirroring dosage increases were
selected.
Pharmacokinetics: sample
preparation and bioanalytical method
Aliquots (10 ml) of plasma and brain homogenate (diluted 1:5
in phosphate buffer) were analysed for JNJ-527 concentrations
using a method based on protein precipitation and HPLC-MS/
MS analysis. To each sample, an internal standard (20 ml) and
acetonitrile (150 ml) were added. Samples were mixed thor-
oughly (mechanical shaking for 10min), and then centrifuged
(5000g for 10min at 4C). An aliquot of supernatant (20 ml)
was dispensed into a LCMS plate and 200ml of 0.1% formic
acid in methanol/water (50:50) were added. Analysis for JNJ-
527 concentrations was performed using HPLC-MS/MS em-
ploying positive-ion electrospray ionization (Sciex API 4000)
and a Zorbaz Eclipse Phenyl Hexyl, 3.5 mm (50  2.1mm in-
ternal diameter) column. Elution was achieved at a ﬂow rate of
0.5ml/min with isocratic elution of 0.1% formic acid in
methanol/water (85:15). The lower limit of quantiﬁcation
was 5–10 ng/ml for plasma and 10 ng/g for brain. The assay
was linear up to 4000 ng/ml for plasma and 4000ng/g for
brain.
Fluorescence-activated cell sorting
analysis
Mice were terminally anaesthetized with an overdose of
sodium pentobarbital and transcardially perfused with hepar-
inized PBS. Spinal cord lumbar segments were harvested in
PBS 2% foetal calf serum 2mM EDTA [ﬂuorescence-acti-
vated cell sorting (FACS) buffer], mechanically triturated
and enzymatically dissociated using the Neural Tissue
Dissociation Kit (P) (Mylteni). Then, samples were passed
through a cell strainer of 70 mm mesh (BD2 Falcon) with
FACS buffer, and centrifuged twice at 500g for 10min at
4C. After the second wash, cells were resuspended in 37%
Percoll (GE Healthcare) and centrifuged at 500g for 30min
at 18C (Pino and Cardona, 2011; Grabert et al., 2016). The
supernatant and myelin layers were discarded, and the cell
pellet enriched with microglia was resuspended in FACS
buffer. Samples were split in several tubes and immunos-
tained. Primary antibody labelling was performed for 1 h at
4C, using the following primary antibodies: anti-CD11b
(BD Bioscience) and anti-CD45 (BD Bioscience), anti-Ly6C
(BD Bioscience) and anti-CD3 (BD Bioscience), adding 7-ami-
noactinomycin D (7-AAD) as a cell viability marker.
Moreover, unstained cells and isotype-matched control sam-
ples were used to control for autoﬂuorescence and/or non-
speciﬁc binding of antibodies. Samples were run on a BD
FACS Aria Flow cytometer. Data were analysed using
FlowJo software.
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Analysis of gene expression by
quantitative PCR
Mouse T10–L1 spinal cords were dissected from P301S and
wild-type mice under a microscope. Samples were homoge-
nized in TRIzol reagent (Invitrogen), following the manufac-
turer instructions to isolate RNA and as described previously
(Gomez-Nicola et al., 2013; Clayton et al., 2017). The isolated
RNA was quantiﬁed (Nanodrop, Thermo Scientiﬁc) and retro-
transcribed with iScriptTM cDNA Synthesis Kit (Bio-Rad).
cDNA libraries were analysed by RT-PCR using iTaqTM
Universal SYBR Green Supermix (Bio-Rad) for the following
genes (Sigma-Aldrich): Csf1 (NM_007778.4; forward (FW),
agtattgccaaggaggtgtcag; reverse (RV), atctggcatgaagtctccattt),
Csf1r (NM_001037859.2; FW, gcagtaccaccatccacttgta; RV,
gtgagacactgtccttcagtgc), Il34 (NM_00113 5100.1; FW,
ctttgggaaacgagaatttggaga; RV, gcaatcctgtagttgatggggaag), Spi1
(Pu.1) (NM_011355.1; FW, cagaagggcaaccgcaagaa; RV,
gccgctgaactggtaggtga), Cebpa (NM_ 007678.3; FW, agcttacaa-
caggccaggtttc; RV, cggctggcgacatacagtac), Il1b (NM_00836 1.3;
FW, cagacccaccctgca; RV, accgtttttccatcttcttct), Tnfa (NM_013
693; FW: aggcactcccccaaaagatg, RV: ttgctacgacgtgggctac), Il6
(NM_031168.1; FW, tccagaaaccgctatgaagttc; RV, caccagcat-
cagtcccaaga) and Gapdh (NM_008084.2; FW, tgaacgggaagct-
cactgg, RV, tccaccaccctgttgctgta). Data were analysed using the
Ct method, with Gapdh as a housekeeping gene.
RNA sequencing
Library preparation and sequencing
RNA samples with RIN scores from 7.6 to 9 were reverse
transcribed to cDNA. Polyadenylated tail selection was done
using Total Dual RNA-Seq PolyA. cDNA was sequenced
(HiSeq3000/4000) at the Wellcome Trust facility obtaining
75 bp per read. On average, 33M reads were obtained per
samples and a mapping rate of 85%.
Data processing
Transcript abundances were quantiﬁed using Kallisto (kallis-
to_linux-v0.43.1) (Bray et al., 2016) and the corresponding
index from the mouse reference transcriptome. The reference
transcriptome consisted on both cDNA and ncDNA sequences
from ensemble release 90 (Zerbino et al., 2018). We ﬁltered
out sequences from chromosomes (or scaffold) other than
chromosomes 1 to 22, X, Y and MT. For each gene, we ob-
tained a relative transcript abundance (in transcripts per mil-
lion, TPM) using the tximport function/package in R (Soneson
et al., 2016). We then ﬁltered out all the genes with 5 1 TPM
across all samples and focused on protein coding genes. After
ﬁltering, 15 596 genes remained; this gene population was con-
sidered as our background for further analysis. In addition, we
detected a similar number of genes on average in the spinal
cord as among cortical samples (14 423 and 13 594,
respectively).
Differential expression analysis
Differential expression analysis between groups (P301S versus
wild-type; P301S + JNJ-527 versus P301S) were performed sep-
arately for each tissue using DESeq2 (Love et al., 2014). The
model included the number of genes detected per sample and
RIN score (genes detected + RIN score + group) as covariates.
The covariates showed strong correlation with the ﬁrst principal
components (Supplementary Fig. 1). We considered that a gene
was detected when it had at least 1 TPM in a particular sample.
Genes with a false discovery rate (FDR) 50.05 were considered
differentially expressed.
Principal component analysis
Principal component analysis was based on the transformed
gene expression data [Log2 (TPM + 1)] using the prcomp func-
tion from the stats package in R (R Core team, 2017) and
plotted with the scatterplot3d function/R package (Ligges
and Martin, 2003).
Hierarchical clustering
Similarity between gene expression proﬁles given as the
Spearman correlation coefﬁcients (). Ward hierarchical clus-
tering of the samples was calculated based on the Euclidean
distance of 1 .
Gene ontology enrichment analysis
Gene ontology analysis was performed using the
RDAVIDWebService package in R (Fresno and Ferna´ndez,
2013). All gene lists were given in Ensemble gene IDs. We
adjusted our background population to our set of 15 596
genes.
Protein–protein interaction network
We created a combined protein–protein interaction (PPI) net-
work from the following resources: BIOGRID Release 3.4.152
(Stark, 2006) [accessed on 11/09/2017], BIOPLEX 2.0 (Huttlin
et al., 2017) [15/09/2017], CORUM (Ruepp et al., 2009) [14/
09/2017], HITPREDICT (Lo´pez et al., 2015) [11/09/2017],
INBIOMAP (Li et al., 2016) [17/09/2017], INTACT
(Hermjakob, 2004; Orchard et al., 2014) [14/09/2017],
MINT (Licata et al., 2012) [15/09/2017], REACTOME ([18)
[14/09/2017] and STRING 10.5 (Szklarczyk et al., 2017) [15/
09/2017]. From the STRING database, only protein links with
experimental score have been included (i.e. score4 0). The
combined PPI network was constructed summarizing PPIs in
human Ensemble gene IDs. Therefore, to use this combined
PPI network, we went from mouse Ensemble gene IDs to
human Ensemble gene IDs only for the genes with a corres-
ponding one-to-one orthologue in human [according to ensem-
ble release 90 (Zerbino et al., 2018)]. To test for more PPIs in
a subset of genes, we compared 10 000 equally sized random
samples of genes (with a similar degree and CDS length distri-
bution). In each randomization, we measured the number of
PPIs among the genes in the sample. An estimated p-value was
obtained by counting the number of random samples where
the number of PPI was higher than in our focus subset of
genes. PPI network plot was created in Cystoscope (Shannon
et al., 2003).
Cell-type specific gene markers
We have used the cell-type speciﬁc gene markers from
NeuroExpresso combined dataset (Mancarci et al., 2017) (ac-
cessed on 17/12/2017) given in Gene Symbols. We also used
some of the original sets of the mouse cortical subtypes iden-
tiﬁed by Tasic et al. (2016). The Tasic dataset comprise groups
of markers for 23 GABAergic, 19 glutamatergic and seven
non-neuronal types.
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Overlap between differentially expressed genes and
cell-type specific gene markers
We looked for cell-type speciﬁc gene markers among our set of
differentially expressed genes. If we found at least one over-
lapping gene we tested if the observed overlap was higher than
expected by chance. We estimated the expected overlap from
10000 randomizations. In each randomization, a group of
genes of the same size as our focus set of genes were drawn
from our background population and the overlap with a spe-
ciﬁc group of gene markers was measured. A P-value was
estimated based on the number of time that the overlap in
the randomizations was higher than in our focus population.
To adjust for multiple testing, we used the Benjamini and
Hochberg method.
Differences in the average fold change
Additionally, we tested whether the average fold-change (be-
tween P301S and wild-type; or between P301S + JNJ-527 and
P301S) among a speciﬁc set of gene markers was different than
expected by chance. Similarly, we created 10 000 equally-sized
random samples of genes and obtain their average fold-change,
estimated a P-value based on the randomizations and adjust
for multiple testing using the Benjamini and Hochberg method.
Cell type gene expression data
We used three independent gene expression datasets to identify
cell speciﬁc gene expression. A combined microarray dataset
for multiple cell types were downloaded from NeuroExpresso
(Mancarci et al., 2017) (accessed on 11/12/2017) and prepro-
cessed RNA-seq gene expression data from Tasic (Tasic et al.,
2016) also available through NeuroExpresso. Additionally, we
used the preprocessed (FPKM) RNA-seq gene expression data
from the RNA-Sequencing Transcriptome and Splicing
Database of Glia, Neurons, and Vascular Cells of the
Cerebral Cortex (Zhang et al., 2014) (accessed on 11/12/
2017).
General statistics
Data are shown as mean  standard error of the mean (SEM)
and where analysed using the GraphPad Prism 6 software
package (GraphPad Software). Functional data were analysed
using two-way repeated measurements ANOVA with Tukey
post hoc test for multiple comparisons. T-test and one-way
ANOVA was used for the histological, gene expression data,
FACS analysis and protein data, when comparing two or more
than two groups, respectively, followed by a Tukey post hoc
test for multiple comparisons. Differences were considered sig-
niﬁcant at P50.05.
For the pharmacokinetic/pharmacodynamics analysis of JNJ-
527, the number of Iba1-BrdU (cells/mm2), yi, is assumed to
follow a normal distribution
yiNðm; 2Þ ð1Þ
where the mean m is modelled using a hill function:
m ¼ E0 1 C

C þ EC50
 
ð2Þ
where E0 represents the untreated number of cells, i.e. the
vehicle data. Further, a maximal attainable inhibition of
100% is assumed, which means that an extremely large
concentration C would lead to a complete eradication of the
cells. Further, EC50 corresponds to the concentration leading
to a 50% decrease of the number of cells, which is often
referred to as the potency, and  corresponds to the steepness
of this slope. Both the two last parameters are ﬁtted on the
log-scale to reﬂect its underlying statistical properties and sub-
sequently back-transformed. The data is ﬁtted both using the
plasma and the brain concentrations as explanatory variables.
The model is ﬁtted using the procedure nlmixed in SAS. The
model prediction and its 95% conﬁdence intervals were graph-
ically represented using R.
Data availability
The full protein and differential expression analyses performed
on CSF and brain or spinal cord tissue are available in
Supplementary Tables 1 and 2, respectively. The data and
code used in this work will be available upon request.
Results
We used two independent models to address two different
but complementary aspects of the preclinical testing of JNJ-
527. First, we used the ME7-prion model for testing the
basic pharmacology of the compound. The rapid increase
in microglia number and responsiveness to CSF1R inhibi-
tors of the prion model (Gomez-Nicola et al., 2013) was
the most appropriate for testing short- and long-term efﬁ-
cacy, deﬁning pharmacokinetic/pharmacodynamics param-
eters, and providing a set of readouts that could be directly
transferred for the clinical testing of the compound. We
then moved to P301S mice to test the efﬁcacy of JNJ-527
in a model of tau-induced neurodegeneration, which is par-
ticularly relevant for Alzheimer’s disease, frontotemporal
dementia (FTD) and other tau pathologies. Whereas
P301S mice were generated as a model of FTD, they
show predominant tau accumulation in the spinal cord
and brainstem, and develop robust motor neuron path-
ology and motor deﬁcits (Allen et al., 2002; Scattoni
et al., 2010). Previous reports showed strong tau phosphor-
ylation, neurodegeneration and marked neuroinﬂammatory
changes in the spinal cord of these mice, that we expanded
further in the present study (Allen et al., 2002; Bellucci
et al., 2004). Despite some evidence of neurodegeneration
in brain areas such as perirhinal cortex (Yang et al., 2015)
or superﬁcial layers of the motor cortex (Hampton et al.,
2010), we focused our attention on the spinal cord, as we
believe it gives rise to readily assayed behavioural and cel-
lular phenotype to dissect the contribution of microglial
proliferation on tau-induced neurodegeneration.
JNJ-527 prevents CSF1R
phosphorylation in N13 microglial
cells
First, we characterized the effect of the selective CSF1R
inhibitor JNJ-527 on CSF1R activation in vitro. We
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stimulated N13 murine microglia cells with CSF1 (100 ng/
ml) to induce tyrosine phosphorylation of CSF1R. Pre-in-
cubation of the cells with a range of concentrations of JNJ-
527 (0.1–103nM) resulted in a dose-dependent decrease of
CSF1R activation and a concurrent reduction of ERK1 and
ERK2 phosphorylation, which are prominent intracellular
signalling pathways downstream of CSF1R (Fig. 1A and B).
We then generated a dose response curve for the effect of
JNJ-527 on CSF1R and ERK1/2, and determined the IC50
to be 18.6 nM for inhibition of CSF1R and 22.5 nM for
ERK1/2 (Fig. 1C). This demonstrates that JNJ-527 is able
to prevent CSF1R phosphorylation, and activation of sub-
sequent downstream pathways.
JNJ-527 does not affect microglial
numbers when administered below
100 mg/kg
Having demonstrated that JNJ-527 is an effective inhibitor
of CSF1R in vitro, we turned to in vivo experiments and
sought to determine its impact on the microglia population
in the healthy brain. We performed a short-term study by
daily administration of JNJ-527 to naı¨ve mice by oral
gavage for ﬁve consecutive days and at four different
doses: 3, 10, 30, 100mg/kg, and vehicle per os (p.o.). In
the brain, JNJ-527 signiﬁcantly diminished the number of
microglia (total CD45+ CD11b+ cells) only at the highest
dose tested of 100mg/kg (Supplementary Fig. 2C). In
contrast, we found that JNJ-527 depleted up to 50% of
patrolling blood monocytes at every dose tested (CD45 +
CD11bhigh Ly6Cintermediate/low cells) with only a tendency
for a reduction in the proportion of inﬂammatory
monocytes (Ly6Chigh cells) at 100mg/kg (P = 0.1)
(Supplementary Fig. 2D). These data suggest that JNJ-527
administered below 100mg/kg does not alter the dynamics
of the homeostatic microglial population.
CSF1R inhibition by JNJ-527 blocks
microglial proliferation in ME7-prion
mice
We then sought to assess the effect of JNJ-527 on microglial
proliferation. Previously, we have demonstrated that micro-
glial proliferation and associated phenotypic changes play a
crucial role in the pathology of ME7-prion disease, and that
this process is driven by the activation of CSF1R (Gomez-
Nicola et al., 2013). The rapid expansion of the microglial
population in this model makes it a suitable platform to
determine drug efﬁcacy in short-term studies (Gomez-
Nicola et al., 2013). Therefore, we assessed the potential
of JNJ-527 to block microglial proliferation in vivo in
ME7-prion mice. Based on previous experiments from our
group (Gomez-Nicola et al., 2013), we performed a dose-
response experiment by treating ME7 mice from 12 weeks
post-induction (wpi) for ﬁve consecutive days with JNJ-527
at doses of 3, 10, 30, 100mg/kg p.o., and vehicle. Mice also
received four daily injections of BrdU to trace proliferating
cells during the treatment period (Fig. 1D). We analysed the
concentration of the compound in brain and plasma and
found a linear dose dependent increase in JNJ-527 exposure,
with an average brain to plasma ratio of 0.65 (Fig. 1E). We
then assessed the impact of CSF1R blockade by JNJ-527 on
microglial proliferation. We found that JNJ-527 signiﬁcantly
inhibited microglial proliferation (Iba1 + BrdU+ cells) in the
hippocampus of ME7 mice from 3mg/kg, reaching a max-
imum effect of 80% inhibition at 30mg/kg (Fig. 1F and G).
Based on these data, we generated a sigmoid Emax pharma-
cokinetic/pharmacodynamics model for inhibition of micro-
glial proliferation and determined that JNJ-527 EC50 was
196ng/ml or 69ng/g for plasma and brain exposures, re-
spectively (Fig. 1H). Overall, we demonstrated that JNJ-
527 administered at 30mg/kg signiﬁcantly blocks microglial
proliferation in ME7-prion mice, without altering the dy-
namics of the population in the healthy brain
(Supplementary Fig. 2C and D). Therefore, we used a dose
of 30mg/kg for all subsequent experiments.
Inhibition of CSF1R by JNJ-527 limits
microglial expansion and attenuates
behavioural deficits in ME7-prion
mice
After determining the optimal treatment dose of JNJ-527,
we aimed to conﬁrm that the blockade of microglial pro-
liferation translates into a long-term effect when tested
under pathological conditions. We performed a 4-week
treatment with JNJ-527 at 30mg/kg in ME7-prion mice
from 12 wpi. We selected this treatment regime based on
our previous work showing a 4-fold increase in the
number of microglia after 4 weeks of prion induction
(Gomez-Nicola et al., 2013). Long-term blockade of
CSF1R signiﬁcantly reduced the density of microglia in
CA1 of the hippocampus of ME7-prion mice (PU.1+
cells) by up to 30% (Fig. 2A). This was accompanied
by a signiﬁcant reduction in the expression of IL1-b
(Fig. 2B), but not other inﬂammatory cytokines
(Supplementary Fig. 3). Previously, we have shown that
ME7 mice develop a highly reproducible disease course
characterized by an early onset associated with anhedonia
(12 wpi), and followed by hyperactivity and motor dys-
function (Guenther et al., 2001; Boche et al., 2006;
Gomez-Nicola et al., 2013). The reduction in the micro-
glial population induced by JNJ-527 led to an attenuation
of hyperactivity and a complete prevention of motor def-
icits (Fig. 2C).
Overall, long-term blockade of CSF1R by JNJ-527 was
able to limit the expansion of the microglial population,
modify the inﬂammatory response and ameliorate the dis-
ease course in vivo in ME7-prion mice.
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Figure 1 JNJ-527 prevents CSF1R phosphorylation in vitro and blocks microglial proliferation in vivo. (A) Representative western
blot of N13 cells pretreated with increasing concentrations of JNJ-527 and stimulated with CSF1. (B) Quantification shows that JNJ-527 inhibits
CSF1-R phosphorylation and downstream ERK1/2 activation at concentrations higher than 10 nM. Experiments were performed in triplicate, and
values were corrected by the untreated control (white bars) and expressed as mean  SEM. (C) JNJ-527 IC50 is within 18.6 and 22.5 nM.
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Proof of target engagement and
efficacy for the potential clinical
assessment of JNJ-527
Given the suitability of the ME7-prion model to study the
effect of JNJ-527 at both short- (5 days) and long-term (4
weeks), we explored a number of readouts with potential
application in clinical studies. We determined the extent
of JNJ-527 target engagement in the systemic compart-
ment by measuring the levels of CSF1 in plasma, as it
was reported previously that chronic blockade of
CSF1R in humans results in a 6-fold increase in plasma
CSF1 due to the lack of internalization by the receptor
(Genovese et al., 2015). Using the same experimental set
up described above, we found that 5 days CSF1R block-
ade by JNJ-527 led to a 30–40% increase in the levels of
Figure 2 Inhibition of CSF1R by JNJ-527 reduces microglial expansion and restores behavioural alterations in ME7 mice.
(A) Long-term JNJ-527 resulted in a significant reduction in the number of microglia (PU.1) in CA1 of the hippocampus. Representative images of
PU.1 staining in CA1 hippocampus of NBH, ME7 and ME7 + JNJ-527 mice. Scale bar = 50mm. (B) JNJ-527 treatment diminished the expression of
IL1-b and (C) attenuated the hyperactive behaviour (locomotor activity) and completely prevented the onset of motor deficits (inverted screen
and horizontal bar). For all quantifications, NBH n = 10, ME7 n = 8, ME7 + JNJ-527 n = 9. Values are mean  SEM. *P5 0.05 ***P5 0.001 versus
NBH; #P5 0.05 versus ME7.
Figure 1 Continued
(D) Schematic representation of the experimental design used for assessing JNJ-527 efficacy in blocking microglial proliferation (NBH n = 8,
NBH + JNJ-527 30 mg/kg n = 6, ME7 n = 14, ME7 + JNJ-527 3 mg/kg n = 6, ME7 + JNJ-527 10 mg/kg n = 6, ME7 + JNJ-527 30 mg/kg n = 8, ME7 + JNJ-
527 100 mg/kg n = 6). Mice were treated with JNJ-527 at different doses (3, 10, 30 and 100 mg/kg) for 5 days, with four daily injections of BrdU to
quantify microglial proliferation. (E) Levels of the JNJ-527 were analysed at the end of the treatment. Both plasma and brain concentration linearly
correlated with the treatment dose, with T/P ratios of 0.5–1 (see numbers above columns). (F and G) JNJ-527 treatment significantly inhibited
microglial proliferation in ME7 mice. Images represent Iba-1 (DAB, brown) and BrdU (alkaline phosphatese, blue) immunohistochemistry with
arrows pointing to Iba-1 + BrdU + proliferating microglia. Quantification of proliferating microglia (Iba-1 + BrdU + cells/mm2) showed a sig-
nificant reduction at all doses tested. Subsequent analysis between different doses revealed a grester effect at 30 and 100 mg/kg.
(H) Pharmacokinetic/pharmacodynamics (PK/PD) model generated from the microglial proliferation data showed an EC50 of 196/ml and 69 ng/g
calculated from plasmatic and brain compound concentration, respectively. (*P5 0.05, **P5 0.01 and ***P5 0.001 versus NBH; #P5 0.05,
##P5 0.01 and ###P5 0.001 versus ME7).
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CSF1 in ME7-prion (Fig. 3A). The same analysis per-
formed on plasma samples of ME7-prion mice treated
during 4 weeks also showed a signiﬁcant increase of
30% in the plasma levels of CSF1 (Fig. 3B). This
demonstrates successful and sustained peripheral target
engagement of JNJ-527.
Next, we set out to determine target engagement and
efﬁcacy of JNJ-527 in the CNS. For assessing target
Figure 3 Target engagement and efficacy readouts for clinical testing of JNJ-527. (A and B) Quantification of CSF1 in plasma was
used as a measure of peripheral target engagement. (A) Short-term (5 days) administration of JNJ-527 administration induced an increase of
plasma CSF1 (NBH n = 8, ME7 + JNJ-527 10 mg/kg n = 6, ME7 + JNJ-527 30 mg/kg). (B) Long-term JNJ-527 administration (4 weeks) showed
similar increments in plasma CSF1, reflecting consistent and long lasting target engagement in the systemic compartment (NBH n = 10, ME7 n = 8,
ME7 + JNJ-527 n = 9). (C) Assessment of target engagement by JNJ-527 in the CNS. CSF high dimensionality proteomics with aptamer capture
arrays showed a dose dependent alteration in IL-34 and SEMA3E (FDR P5 9.19  1013), among 67 other proteins (NBH n = 29, ME7 n = 30,
with each type receiving JNJ-527 doses: vehicle n = 10; 10 mg/kg n = 10; 30 mg/kg n = 9, 10). (D) Analysis of long-term efficacy by TSPO imaging
after long-term treatment with JNJ-527. TSPO autoradiography with [3H]-PK11195 performed in different brain regions showed a consistent
increase of signal in ME7 versus NBH mice, and an attenuation after treatment with JNJ-527 (NBH n = 10, ME7 n = 8, ME7 + JNJ-527 n = 9). For all
graphs, values are mean  SEM. *P5 0.05, **P5 0.01, ***P5 0.001 versus NBH; #P5 0.05 versus ME7.
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engagement in the brain, we used high dimensionality
proteomics with aptamer capture arrays to determine dif-
ferential expression of multiple proteins in CSF from both
ME7 and NBH mice subjected to 5 days treatment with
increasing doses of JNJ-527. We detected a dose dependent
increase in IL-34, and SEMA3E (FDR P5 9.19  1013;
Fig. 3C) and 67 other proteins (Supplementary Table 1).
Interestingly, IL-34 is one of the ligands of CSF1R and its
increase in response to JNJ-527 shows a clear effect of
compound on its intended target in the brain. CSF1 was
not determined in this assay because the human speciﬁc
probes used were not cross-reactive with the murine
CSF1. In addition, we explored protein-wide expression
changes further by using pathway enrichment for our ex-
perimental comparisons. The most signiﬁcantly enriched
pathways in response to increasing doses of JNJ-527
included axon guidance (P = 0.00019), cell adhesion
(P = 0.00452) and extracellular matrix-receptor interactions
(P = 0.00014) as well as complement and coagulation cas-
cades (P = 0.00175); the latter an important immune re-
sponse pathway (Supplementary Table 1).
Finally, we assessed the long-term efﬁcacy of JNJ-527 in
the brain by performing autoradiography on tissue sections
using the TSPO ligand 3H-PK11195. Mitochondrial TSPO
(18-kDa translocator protein) is a widely used imaging bio-
marker of neuroinﬂammation in humans and animal
models, and its increased expression is linked to microglial
activation, although TSPO can also be expressed in other
immune and endothelial cells in the CNS (Turkheimer
et al., 2015). We found that the TSPO signal was signiﬁ-
cantly increased (4100%) in the hippocampus, somatosen-
sory cortex and thalamus of ME7 versus NBH mice, and
this increase was attenuated after the treatment with JNJ-
527 (Fig. 3D). The 30% reduction in TSPO signal observed
in the hippocampus parallels the reduction of microglial
numbers after long-term treatment with JNJ-527
(Fig. 2A). These data provide evidence for sustained en-
gagement and efﬁcacy of JNJ-527 in the brain.
Tau phosphorylation and
degeneration of motor neurons are
associated with an inflammatory
reaction in P301S mice
As we had demonstrated the anti-proliferative effect of JNJ-
527 in ME7 mice, we investigated the potential impact of
blockade on CSF1R in the P301S mouse model of tauopa-
thy. Building on previous studies of this model (Allen et al.,
2002; Bellucci et al., 2004; Hampton et al., 2010), we per-
formed a longitudinal analysis ﬁrst to conﬁrm the dynamics
of tau phosphorylation, neurodegeneration and microglial
activation in the spinal cord of P301S mice to deﬁne a
suitable therapeutic window for intervention with JNJ-
527. We conﬁrmed accumulation of phosphorylated tau
in P301S mice at different time points, analysed by different
phosphorylated epitopes (AT8, AT100 and AT180).
Interestingly, different phospho-epitopes displayed variable
patterns of change during the disease process, with an ear-
lier increase at AT100 epitopes from 12 weeks of age
(Supplementary Fig. 4A). We studied the speciﬁc localiza-
tion of AT8 and AT100 phosphorylated tau in L4–L5 seg-
ments of P301S mice spinal cord and found the ﬁrst sign of
phospho-tau accumulation in spinal motor neurons at 12
weeks of age, which then spread throughout all the anterior
spinal horn by 20 weeks (Supplementary Fig. 4B). The pat-
tern of increased tau phosphorylation paralleled a signiﬁ-
cant loss of motor neurons from 12 weeks of age that
progresses up to a 40% loss at end stages of the disease
(Supplementary Fig. 4C).
An increased number of microglia is a hallmark of dis-
ease progression in mouse models of Alzheimer’s disease
(Olmos-Alonso et al., 2016), FTD (Clayton et al., 2017),
ALS (Martinez-Muriana et al., 2016) and prion disease
(Gomez-Nicola et al., 2013). Similarly, in the P301S
model, we quantiﬁed microglia in the spinal cord of
P301S mice and found a consistent 2–3-fold increase in
the number of cells by both ﬂow cytometry (CD11b +
CD45+ cells) and in the density of cells by histology
(PU.1 cells) (Fig. 4A and D). We also investigated a poten-
tial contribution of peripheral immune cells, and ruled out
a signiﬁcant inﬂux of monocytes (CD45 + CD11b+
Ly6C+ cells) or T-cells (CD45+ CD3+ cells) inﬁltrating
the spinal cord of these mice (Fig. 4B and C), and therefore
we considered the totality of CD11b + CD45+ cells as
microglia. Interestingly, we did not observe any differential
increase in microglia density across spinal cord regions,
with a similar magnitude of change in thoracic, lumbar
and sacral spinal segments in disease progression
(Fig. 4D). Further histological analysis revealed an early
increase in the Iba-1 staining area in the anterior regions
of the spinal cord from 12 weeks of age, both in the grey
matter and the ventrolateral funiculus (Fig. 4E). The
changes in the microglial population were accompanied
by a signiﬁcantly increased expression of pro-inﬂammatory
cytokines IL-1b and TNFa, the former being overexpressed
from early pre-symptomatic stages (Fig. 4F), but not other
cytokines (Supplementary Fig. 5). This suggests that micro-
glia undergo phenotypic changes in response to neurode-
generation that are then followed by increased
proliferation.
It has been shown previously that inﬂammatory cyto-
kines, especially IL-1b, can contribute to tau phosphoryl-
ation by the activation of MAPK in neurons in hTau mice
(Maphis et al., 2015, 2016). Therefore, we explored the
levels of activation of JNK (phospho-JNK) and p38
(phospho-p38) in spinal motor neurons of P301S mice,
identiﬁed as those present in lamina IX with diameters
larger than 20 mm, polygonal shape and prominent nucleoli.
We found an age-dependent increase in the number of both
phospho-JNK and phosho-p38 positive motor neurons in
the L4-L5 segments of the spinal cord (Fig. 4G and H),
which follows the same pattern as the increase of phos-
phorylated tau (Supplementary Fig. 4A and B).
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Figure 4 Tau phosphorylation and degeneration of motor neurons is accompanied by an inflammatory reaction in the
spinal cord of P301S mice. (A) Significant increase in the number of microglia in the spinal cord of 20-week-old P301S mice, with no
evidence of (B) infiltration of monocytes or (C) T cells [CD11b + CD45 + cells, wild-type (WT)-20 weeks n = 13, P301S-6 weeks n = 6, P301S-
12 weeks n = 8, P301S-20 weeks n = 6]. (D) The increase in the number of microglia is similar between different regions of the spinal cord.
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Interestingly, whereas in wild-type or early pre-symptom-
atic P301S mice (6 weeks) phospho-MAPK expression is
localized in the nucleus of the cells (Fig. 4G and H), it
then shifts to the cytoplasmic compartment from 12
weeks of age where MAPK could contribute to tau phos-
phorylation. Overall, our data suggest that inﬂammatory
changes in the spinal cord parallel tau phosphorylation
and degeneration of motor neurons, with ﬁrst signs of al-
terations from 12 weeks of age.
Blockade of CSF1R by JNJ-527
reduces microglial numbers and the
expression of pro-inflammatory
cytokines in P301S mice
Since we had demonstrated that JNJ-527 was able to
block microglial proliferation in vivo, we tested whether
preventing microglial proliferation had an impact in the
pathology of P301S tau transgenic mice. Given that we
detected the ﬁrst pathological signs in the spinal cord of
P301S mice from 12 weeks of age, we performed a long-
term preventive treatment from 8 to 16 weeks of age
(Fig. 5A). Blockade of CSF1R in P301S mice led to a
signiﬁcant reduction in the number of cells, evidenced by
40% decrease in the number of microglial and macro-
phages (CD11b + CD45 + ) in the lumbar spinal cord
(Fig. 5B). The reduction in the number of microglia
was accompanied by a signiﬁcantly diminished expres-
sion of multiple genes controlling microglial prolifer-
ation, including Csf1r and Spi1 (Pu.1) (Fig. 5C). These
effects resembled those reported in other models of neu-
rodegeneration including prion disease (Gomez-Nicola
et al., 2013) and mSOD1 ALS mice (Martinez-Muriana
et al., 2016) and while they may reﬂect a reduction in
the number of microglia, we cannot exclude a dimin-
ished expression of these genes per cell. JNJ-527 also
caused a signiﬁcant reduction of the expression of
IL1b and TNFa (Fig. 5D and E), without altering the
levels of other cytokines (Supplementary Fig. 5). We
then investigated whether the attenuation in the expres-
sion of inﬂammatory cytokines by JNJ-527 had any
impact on the activation of JNK (phospho-JNK) and
p38 (phospho-p38) in spinal motor neurons of P301S
mice, which were identiﬁed by location, morphology
and size: only polygonal cells with a diameter 420 mm
and located in spinal lamina IX were counted. In both
cases, we found a signiﬁcant reduction of 60% and 40%
in the density of motor neurons with cytoplasmic phos-
pho-JNK or phospho-p38 expression in L4-L5 segments
of the spinal cord, respectively (Fig. 5F and G). Our
results show that JNJ-527 blocks microglial prolifer-
ation, attenuates the inﬂammatory response and modi-
ﬁes kinases activation in motor neurons in the P301S
spinal cord.
The reduction in the number of
microglia impacts tau pathology and
prevents motor neuron degeneration
in P301S mice
We then assessed whether blockade of microglial prolifer-
ation and modiﬁcation of the inﬂammatory milieu by JNJ-
527 had an impact on the neuropathology in the P301S
spinal cord. Western blot analysis showed that treatment
with JNJ-527 caused a signiﬁcant reduction in the phos-
phorylation of tau at AT8 sites (Fig. 6A). We then per-
formed protein fractionation to investigate the presence of
granular tau oligomers or neuroﬁbrillary tangles. Spinal
cord homogenates were spun at speeds known to pellet
either granular tau oligomers or larger tau ﬁbrils (Cowan
et al., 2015), which were then dissolved in sarkosyl and
termed the S3 and NS2 fractions, respectively. Mice treated
with JNJ-527 showed a signiﬁcant reduction in the insol-
uble NS2 fraction of larger tau ﬁbrils and a trend towards
a reduction in the insoluble NS3 fraction of globular tau
oligomers (Fig. 6B). Additionally, we used a second bio-
chemical method, an MSD immunoassay, to evaluate the
amount of aggregated tau in the total homogenate of the
spinal cord of the P301S mice. This aggregation assay con-
sisted in a sandwich immunoassay with the same antibody
used for coating as for detection. As such, both antibodies
can only bind if multimers of tau are detected. Two aggre-
gation assays were performed. One with the AT8 antibody
to detect aggregates containing phospho-tau, and one with
a total tau antibody binding in the proline riche domain to
detect all aggregates, independent of their phosphorylation
Figure 4 Continued
Scale bar = 100 mm. Higher magnification in boxes are shown in 1–4. Scale bar = 25 mm (WT-20 weeks n = 5, P301S-6weeks n = 4, P301S-12weeks
n = 5, P301S-20 weeks n = 4). (E) Morphological changes in microglia precede the increase in their number both in the white and grey matter of
P301S spinal cord. Scale bar = 200 mm. Higher magnification in boxes are shown in 1–4. Scale bar, 25mm (wild-type-20 weeks n = 5, P301S-6weeks
n = 4, P301S-12weeks n = 5, P301S-20 weeks n = 4). (F) IL-1b and TNFa are significantly increased in the spinal cord of P301S mice, correlating
with the degeneration of motor neurons (wild-type-20 weeks n = 10, P301S-6 weeks n = 5, P301S-12 weeks n = 4, P301S-20 weeks n = 4). (G and
H) Activation of JNK (phospho-JNK) in the spinal cord of wild-type and P301S mice (wild-type-20 weeks n = 5, P301S-6 weeks n = 4, P301S-12
weeks n = 5, P301S-20 weeks n = 4). (G) Cytoplasmic accumulation of phospho-JNK in motor neurons starts by 12 weeks of age (arrows) and
later affects both motor neurons and other smaller populations of neurons in the spinal cord. (H) Activation of p38 (phospho-p38) shows a
similar pattern, with a translocation from the nucleus (asterisk) to the cytoplasm (arrows) of motor neurons of P301S mice from 12 weeks of age.
Scale bar = 20mm. Values are mean  SEM. *P5 0.05, **P5 0.01 and P5 0.001 versus wild-type.
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status. Furthermore, two sandwich immunoassays for total
tau were performed. One with two non-competing antibo-
dies with their epitope slightly N-terminal of the proline-
rich domain and one with an antibody binding in the N-
terminal region of tau and the other antibody binding in
the proline-rich domain. Whereas both aggregation assays
Figure 5 JNJ-527 reduces microglial expansion and the expression of pro-inflammatory cytokines in P301S mice. (A) Schematic
representation of the experimental design used to test the efficacy of CSF1-R blockade in P301S mice. Animals were treated for 8 weeks with JNJ-
527 at a dose of 30 mg/kg. (B) JNJ-527 treatment reduced the number of CD11b + CD45 + cells in the spinal cord of P301S mice [wild-type (WT)
n = 7, P301S n = 11, P301S + JNJ-527 n = 6]. (C) JNJ-527 treated mice showed a significant reduction in the expression of genes associated with
microglial proliferation (wild-type n = 10, P301S n = 8, P301S + JNJ-527 n = 9). (D and E) The reduction in the number of microglia was correlated
with a reduction of IL1-b and TNFa at (D) RNA and (E) protein level (wild-type n = 10, P301S n = 8, P301S + JNJ-527 n = 9). (F and G)
Diminished expression of inflammatory cytokines correlated with reduced activation of JNK and p38 in the cytoplasm of spinal motor neurons of
16 weeks old P301S mice (P301S n = 9, P301S + JNJ-527 n = 10). Scale bar = 50mm. Values are mean  SEM. *P5 0.05, **P5 0.01 and
***P5 0.001 versus P301S.
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show no changes in the absolute values of aggregated tau
in animals treated with JNJ-527, we found a tendency to-
wards a reduction when corrected by total tau (Fig. 6C).
Treatment with JNJ-527 also led to a signiﬁcant preserva-
tion of motor neurons located in the spinal cord (Fig. 6D),
and a signiﬁcant improvement of motor function (Fig. 6E).
Figure 6 Chronic blockade of CSF1R impacts tau pathology, prevents spinal motor neuron degeneration and improves motor
function of P301S mice. JNJ-527 administration reduced (A) tau phosphorylation (AT8) and (B) aggregation in the form of neurofibrillary
tangles (neurofibrillary tangles, P301S n = 4, P301S + JNJ-527 n = 5) and globular tau oligomers (globular tau oligomers, P301S n = 5, P301S + JNJ-
527 n = 5). Values are mean  SEM. *P5 0.05, **P5 0.01 and ***P5 0.001 versus P301S. (C) JNJ-527 treatment induced a trend of tau
aggregation reduction as measured by MSD and did not show an effect on total tau. Graphs are represented as mean  SEM and the P-value from
an unpaired t-test is indicated in the respective graphs, with near significant values outlined (P301S n = 9, P301S + JNJ-527 n = 10). (D)
Quantification of motor neuron by Nissl staining showed increased neuronal preservation in L4–L5 spinal segments of 16 weeks old P301S mice
after JNJ-527 treatment (wild-type n = 10, P301S n = 9, P301S + JNJ-527 n = 10), whereas (E) rotarod test showed improved motor function in
JNJ-527 treated mice (wild-type n = 20, P301S n = 20, P301S + JNJ-527 n = 21). Scale bar = 50 mm. For the neuronal survival and functional
analysis, values are mean  SEM. ***P5 0.001 versus wild type; ##P5 0.01 and ###P5 0.001 JNJ-527 versus P301S.
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Overall, these results demonstrate that the blockade of
microglial proliferation by JNJ-527 might lead to attenu-
ation of tau pathology and results in a reduction of neur-
onal cell death in P301S mice.
JNJ-527 modifies the transcriptomic
profile of the P301S mice spinal cord
Next, we sought to analyse the effect of JNJ-527 in the
P301S mice at the transcriptomic level to determine
whether the reduction in microglial numbers was also asso-
ciated with a phenotypic change that could underpin the
effects seen on tau pathology and neuronal preservation.
In the ﬁrst instance, both spinal cord and cortical samples
were used to assess the impact of JNJ-527 (Supplementary
Fig. 7A). Principal component analysis of the gene expres-
sion data showed that the ﬁrst principal component (PC1)
divided our samples by tissue and the second principal
component (PC2) distinguished between P301S and wild
type mice (Supplementary Fig. 7B). Similarly, the main
branching point obtained by hierarchical clustering also
divided the samples according to tissue (Supplementary
Fig. 8). Taking into account that PC1 alone explained
about 80% of the variance we decided to carry out differ-
ential expression analysis separately for the spinal cord and
the cortex.
We compared the expression proﬁle of wild-type versus
P301S mice and found 900 (542 up- and 358 downregu-
lated) and 944 (432 up- and 512 downregulated) differen-
tially expressed genes in the spinal cord and cortex,
respectively (FDR5 0.05). From these, 297 genes were dif-
ferentially expressed in both tissues, which represents a
higher overlap than that expected by chance (ex-
pected = 54.527, P5 1  104) and indicates a degree of
consistency of the transcriptomic disease signal across tis-
sues (Supplementary Fig. 7C and Supplementary Table 2).
Then, we focused on the effect of the JNJ-527 on the
P301S tau mice. Strikingly, only one gene was differentially
expressed in the cortex after the treatment, whereas 50
genes showed a signiﬁcant response in the spinal cord
(Fig. 7A and Supplementary Fig. 7C, FDR5 0.05), which
reﬂects a selective impact of JNJ-527 in regions associated
with increased microglial proliferation (Fig. 4A and D).
Further analysis of the expression of those 42 JNJ-527
responsive genes in the spinal cord showed that all of them
had opposing directions in disease and treatment. The vast
majority of them (41 genes of 49) were upregulated in dis-
ease and downregulated with treatment, with only the
Atx2nl gene as the exception, which followed the opposite
pattern, downregulated in disease and upregulated after
treatment (Fig. 7A and B). By using a well-characterized
set of cell-type speciﬁc markers from NeuroExpresso
(Mancarci et al., 2017), we looked for an overlap with
known cell-type speciﬁc markers. Almost all genes
showed a preference of expression in microglial cells. The
only exceptions were Rida and S100a1, which showed the
highest expression in Bergmann cells (Supplementary Fig.
9A), and Apoe, which showed very low expression in
microglia in the healthy brain, but has been shown to be
one of the most upregulated factors in disease-associated
microglia (Keren-Shaul et al., 2017; Krasemann et al.,
2017). We conﬁrmed the cell-speciﬁc expression patterns
of our set of 41 genes using two additional compilations
from RNA-seq data (Supplementary Fig. 9B and C).
Interestingly, a signiﬁcant proportion of downregulated
genes after JNJ-527 treatment are characteristic of the dis-
ease associated response that has been previously described
in multiple models of disease, including P301S mice
(Friedman et al., 2018), such as Apoe, Rplp2, Ctss,
Tyrobp, Lyz2, Fcer1g, Trem2, Mpeg2, Cd52, Plek and
Cd84 (for only two homeostatic microglial markers,
Hexb and Tgfb1) (Keren-Shaul et al., 2017; Krasemann
et al., 2017). Although we cannot exclude the possibility
that this effect is due to a reduction in the density of micro-
glia, it likely also reﬂect a shift in the transcriptomic proﬁle
of the remaining microglial cells, and raises interesting
questions as to whether diminishing this disease-associated
phenotype may have a beneﬁcial effect in the context of
neurodegeneration.
Transcriptomic changes elicited by
JNJ-527 involve immune networks
with CSF1R as hub
Given the consistency of the treatment in reversing the
transcriptomic proﬁle of the disease, we looked for func-
tional associations, ﬁrst using pathway analysis and then
using interaction analyses. Gene Ontology (GO) enrichment
analysis revealed a strong immune related signature with
the top ten enriched biological processes all related to im-
munity, and more than 50% of the genes (42) annotated to
‘immune system process’ (Fig. 7C).
Finally, we assessed whether the protein products of the
41 genes are known to interact with each other. Thus,
combining diverse datasets we created an integrated PPI
network for human and found 22 known PPIs among the
41 genes. The number of PPIs detected was higher than
that expected by chance, as estimated by 10 000 random
permutations (P5 0.0001). As expected, CSF1R was a hub
in the PPI network participating in half of the known PPIs
(Fig. 7D).
Discussion
In this study we used two complementary animal models of
protein misfolding neurodegenerative disease, with a prom-
inent contribution of microglia, to validate the new select-
ive CSF1R inhibitor JNJ-527 for the blockade of microglial
proliferation and assess its efﬁcacy in tau-induced neurode-
generation. We ﬁrst used the ME7 prion model, which pre-
sents a rapid expansion of microglia that is at least partially
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driven by CSF1R (Gomez-Nicola et al., 2013), and showed
that JNJ-527 is brain penetrant, affects microglial prolifer-
ation in a dose dependent manner, and elicits changes in
microglia that can be detected by clinically relevant read-
outs, including TSPO PET ligand binding and CSF
proteomics, which are highly translational and add signiﬁ-
cant value for the preparation of further clinical studies.
We then moved to a more relevant model for tauopathies
and Alzheimer’s disease and assessed the impact of CSF1R
inhibition by JNJ-527 in P301S mice. We showed that
Figure 7 Differentially expressed genes driven by JNJ-527 in the spinal cord of P301S mice. (A) Venn diagrams showing opposing
patterns of expression in disease (P301S versus wild-type) and treatment (P301S + JNJ-527 versus P301S) in the spinal cord (wild-type n = 7,
P301S n = 3, P301S + JNJ-527 n = 5). Briefly, 542 genes were upregulated (left) and 358 were downregulated (right) in the spinal cord of P301S
mice. Of those genes, 42 recovered normal expression levels after chronic treatment with JNJ-527 (in purple). (B) FDR for top 10 biological
processes overrepresented among the 41 genes upregulated in disease and downregulated with JNJ-527 treatment, the size of the circles reflects
the number of genes annotated in each gene ontology (GO) term while the colour indicates the fold enrichment. (C) Heat map showing the gene
expression patterns in the spinal cord samples for the overlapping genes shown in A, genes are ordered from top to bottom according to their
average expression [log2 (TPM + 1)]. (D) From the aforementioned 41 genes, we selected those with a one-to-one orthologue in human and
looked for known PPIs among them. The network shows the 22 known PPIs among the targeted genes, with CSF1R as a relevant hub.
18 | BRAIN 2019: 0; 1–22 R. Mancuso et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
z241/5554563 by U
niversity of C
ardiff - Journal of Biochem
isty Trial user on 28 August 2019
blocking the expansion of microglia impacts microglial
phenotype and the CNS inﬂammatory milieu, and may
ameliorate tau pathology, attenuates neurodegeneration
and results in functional improvement. Overall, our study
establishes the potential for clinical application of the
CSF1R inhibitor JNJ-527 in Alzheimer’s disease and
other neurodegenerative disorders where neuroinﬂamma-
tion may play a role.
The importance of neuroinﬂammation and microglia in
Alzheimer’s disease has been highlighted by multiple
GWAS, which have identiﬁed a number of single poly-
morphisms associated with risk for development of
Alzheimer’s disease in several immune related genes, includ-
ing TREM2, CD33, BIN1, and CR1 (Efthymiou and
Goate, 2017). Therefore, understanding the role of micro-
glia in the different aspects of Alzheimer’s disease seems
crucial to develop successful strategies to tackle the disease.
Among the multiple aspects of the inﬂammatory reaction
occurring in the Alzheimer’s disease brain, several studies
have highlighted the contribution of microglial proliferation
as a signiﬁcant pathogenic process (Spangenberg and
Green, 2017). Either blockade of proliferation or partial
ablation of microglia in APP/PS1 (Olmos-Alonso et al.,
2016), 3xTg-AD (Dagher et al., 2015) and 5xTgAD
(Spangenberg et al., 2016; Sosna et al., 2018) models re-
sulted in prevention of synaptic pathology and attenuation
of cognitive deﬁcits. However, while these studies have
focused on amyloid-b pathology, the link between neuroin-
ﬂammation and tau pathology, the other major proteino-
pathy in the Alzheimer’s disease brain, or tau-mediated
neurodegeneration remains to be elucidated.
Previous studies have shown that induction of microglial
activation by systemic administration of lipopolysaccharide
or genetic deletion of Cx3cr1 enhances tau phosphoryl-
ation/aggregation in both wild-type (Bhaskar et al., 2010)
and hTau transgenic mice (Maphis et al., 2015, 2016). In
addition, genetic deletion of Cx3cr1 in hTau mice induces
or increases neuronal loss and cognitive deﬁcits (Maphis
et al., 2015). Abnormal activation of JNK and p38 has
also been reported in motor neurons of P301S mice
(Allen et al., 2002; Bellucci et al., 2004) and inﬂammatory
cytokines, especially IL-1b, can contribute to tau phosphor-
ylation via the activation of MAPK in neurons in hTau
mice (Bhaskar et al., 2010; Maphis et al., 2015, 2016).
Microglia have been also suggested to play a role in tau
propagation across the brain by transferring phosphory-
lated tau from neuron to neuron possibly via exosomes
(Asai et al., 2015). Nevertheless, it is still uncertain whether
microglia have a predominant effect on tau-related path-
ology and whether its modulation may alter disease
course. Here, we show that inhibition of microglial prolif-
eration in P301S mice resulted in a modiﬁcation of the
microglial phenotype, a reduction of inﬂammatory cyto-
kines and an attenuation of MAPK activity in the cyto-
plasm of P301S spinal motor neurons, potentially slowing
down tau aggregation, and preventing neurodegeneration
and motor deﬁcits. Although the blockade of microglial
proliferation seems to have an impact on tau aggregation,
similar strategies have failed to modify the amyloid-b de-
position in APP/PS1 (Olmos-Alonso et al., 2016), 3xTg-AD
(Dagher et al., 2015) and 5xTg-AD (Spangenberg et al.,
2016; Sosna et al., 2018). This may point to a fundamen-
tally different involvement of microglia in pathological pro-
cesses driven by amyloid-b or tau, but recent work from
Sosna et al. (2018) also suggests that this might just be the
result of the selected timing for treatment, since the early
ablation of microglia in 5xTg-AD resulted in a reduction of
soluble and insoluble forms of amyloid-b. Interestingly, it
has also been shown that IL-1b can increase APP synthesis
in human cells by post-transcriptional regulation (without
altering APP mRNA levels) (Rogers et al., 1999), and
therefore the discrepancy in the results obtained from amyl-
oid-b mouse models may also be explained by a disease
stage-dependent involvement of inﬂammatory cytokines.
Here, we provide compelling evidence that activated micro-
glia play a deleterious role within the context of tau-related
diseases and that, in P301S mice, this effect may be at least
partially mediated by the production of inﬂammatory cyto-
kines which have an impact on the physiology of neurons.
Partial depletion of microglia has been also recently tested
in aged Tg2510 but failed to modify tau pathology
(Bennett et al., 2018). Whereas this discrepancy is more
likely because of the particular therapeutic window se-
lected, as the partial microglial depletion was induced
when full tau pathology was already established in the
brain of these mice, it is also plausible that differences
are the result of the nature of the tyrosine kinase inhibitor
used, PLX3397, which shows more selectivity for KIT than
CSF1R (20 nM, 10 nM and 160 nM for CSF1R, KIT and
FLT3, respectively) (DeNardo et al., 2011).
Recent transcriptomics performed on 5xTg-AD (Keren-
Shaul et al., 2017), APP/PS1 (Krasemann et al., 2017)
and P301S (Friedman et al., 2018) mice has shed some
light on the transcriptional signature of disease associated
microglia and brain resident macrophages, in which there is
a switch between a homeostatic signature characterized by
the expression of genes such as Tmem119, P2ry12,
Cx3cr1, and Sall1 to a pathogenic phenotype, which upre-
gulates a very speciﬁc set of genes including Trem2, Apoe,
Csf1, Itgax, Cst7, Clec7a, with Trem2 and especially Apoe
as major drivers of the phenotypic changes (Keren-Shaul
et al., 2017; Krasemann et al., 2017). To gain in-depth
knowledge about the potential mechanism underlying the
positive impact of CSF1R inhibition by JNJ-527, we per-
formed a transcriptomic analysis of the spinal cord of trea-
ted versus untreated P301S mice. We found that the
treatment reduced the expression of several disease-asso-
ciated genes including Apoe, Rplp2, Ctss, Tyrobp, Lyz2,
Fcer1g, Trem2, Mpeg2, Cd52, Plek and CD84 (Keren-
Shaul et al., 2017; Krasemann et al., 2017; Friedman
et al., 2018). Although this may reﬂect a shift in the pheno-
type of the remaining microglia, we cannot exclude that it
is due to a reduction in the density of cells. However, our
ﬁndings suggest that modifying the microglial disease-
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associated phenotype may produce a beneﬁcial impact in
the context of brain disease.
Interestingly, from a functional perspective, both gene
products that might activate microglia through their
ITAM domains (Tyrobp, Trem2, Fcer1g, Fcgr3, Fcrls,
Fcrg1) and genes that inhibit microglia activation
through ITIM domains are downregulated after JNJ-527
treatment. This may reﬂect the duality of detrimental
and protective roles that microglia can acquire in the con-
text of neurodegeneration, which may also play a role in
the beneﬁcial effects we observed in terms of tau path-
ology and neuronal protection. Precisely how the shift in
gene expression is reﬂected in the microglia secretome to
impact on tau-mediated pathology remains to be
established.
An important and often omitted aspect of preclinical re-
search suggesting new therapeutic strategies for neurode-
generative diseases, is the use of speciﬁc tools that can be
transferred to human patients. JNJ-527 is a clinically char-
acterized compound that showed safety and tolerability
when administered to humans (Genovese et al., 2015;
Von Tresckow et al., 2015). We showed that JNJ-527 is
a CNS-penetrant CSF1R inhibitor and established an opti-
mal dose for preclinical applications, and estimate an efﬁ-
cacious dose for further clinical investigations in
neurodegenerative disease. We also showed that measuring
plasma levels of CSF1 is a consistent readout for both
short- and long-term peripheral target engagement by
JNJ-527 (Genovese et al., 2015).
We then performed a set of experiments to determine the
target engagement of JNJ-527 in the CNS. We ﬁrst con-
ducted TSPO autoradiography, as a precursor to the po-
tential in vivo TSPO PET imaging in humans. TSPO is
elevated in activated microglia of the CNS but also in
astrocytes, endothelial cells, macrophages and monocytes
in response to a variety of insults, as well as neurodegen-
erative diseases (Turkheimer et al., 2015). TSPO is one of
the few available imaging biomarkers to detect inﬂamma-
tion in the living human brain. We report for the ﬁrst time
an increase in TSPO binding in the ME7 mouse prion
model. Importantly, TSPO binding was sensitive to the in-
hibition of CSF1R in the ME7 mouse model after JNJ-527
chronic treatment, showing a similar magnitude of change
to the histological and ﬂow cytometry analyses of micro-
glia, and therefore showing promise as a potential clinical
measure of treatment efﬁcacy. We also used high dimen-
sionality proteomics to determine differential expression of
proteins in CSF upon administration of JNJ-527.
Interestingly, we found a dose dependent increase in IL-
34, which is one of the ligands of CSF1R in the CNS.
This parallels the behaviour of CSF1 in plasma and repre-
sents invaluable evidence of target engagement within the
CNS with potential for direct application in clinical studies.
Overall, this study shows that inhibition of microglial
proliferation and modiﬁcation of the inﬂammatory milieu
is able to modify the disease trajectory in the P301S model
of tau-induced neurodegeneration. These ﬁndings have
clear relevance for Alzheimer’s disease, where tau is a
major player, but also other tauopathies including multiple
forms of FTD, and works towards providing a solid base
for future testing of JNJ-527 in the clinic.
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